- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02902965
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brno, Czechia
- Fakultni nemocnice Brno
-
Nový Hradec Králové, Czechia
- Fakultni nemocnice Hradec Kralove
-
Ostrava-Poruba, Czechia
- Fakultni nemocnice Ostrava
-
Praha 2, Czechia
- Všeobecná fakultní nemocnice v Praha
-
-
-
-
-
Berlin, Germany
- Helios-Kliniken Berlin-Buch
-
Berlin, Germany
- Vivantes Klinikum Spandau
-
Jena, Germany
- Universitätsklinikum Jena
-
München, Germany
- Klinikum der Universität München Campus Großhadern
-
-
-
-
-
Athens, Greece
- General Hospital of Athens "Alexandra"
-
Athens, Greece
- 251 General Air Force Hospital
-
Athens, Greece
- General Hospital of Athens "Evangelismos"
-
Athens, Greece
- General Hospital of Athens "LAIKO"
-
Patras, Greece
- University General Hospital of Patra
-
Thessaloniki, Greece
- General Hospital of Thessaloniki "G. Papanikolau"
-
-
-
-
-
Bologna, Italy
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Meldola (FC), Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Ravenna, Italy
- Ospedale Santa Maria delle Croci
-
Rimini, Italy
- Ospedale Degli Infermi
-
Terni, Italy
- Azienda Ospedaliera S. Maria di Terni
-
-
Foggia
-
San Giovanni Rotondo, Foggia, Italy
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
-
-
-
-
A Coruna, Spain
- Complejo Hospitalario Universitario A Coruña
-
Badalona, Spain
- ICO Badalona-Hospital Germans Trias i Pujol
-
Barcelona, Spain
- Hospital Clinic i Provincial de Barcelona
-
Madrid, Spain
- Hospital Universitario Madrid Sanchinarro
-
Pamplona, Spain
- Clinica Universidad de Navarra
-
Salamanca, Spain
- Hospital Universitario de Salamanca
-
Sevilla, Spain
- Hospital Universitario Virgen del Rocío
-
Valencia, Spain
- Hospital Universitario Dr. Peset
-
-
Madrid
-
Mostoles, Madrid, Spain
- Hospital Universitario Rey Juan carlos
-
-
-
-
-
Ankara, Turkey
- Ankara University Medical Faculty
-
Izmir, Turkey
- Dokuz Eylul University Medicine Faculty
-
Kayseri, Turkey
- Erciyes University Medical Faculty
-
Samsun, Turkey
- Ondokuz Mayis Univ. Med. Fac.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with multiple myeloma (MM) who have received 1-3 prior lines of therapy and have demonstrated disease progression since the completion of the most recent treatment regimen. (Subjects may have received prior bortezomib exposure if it does not meet the exclusion criteria for prior proteasome inhibitor use)
Measurable disease defined by at least one of the following:
- Serum monoclonal protein (SPEP) ≥1 g/dL (for subjects with immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE) or immunoglobulin M (IgM) multiple myeloma SPEP ≥0.5 g/dL)
- Urine monoclonal protein (UPEP) ≥200 mg by 24 hour urine electrophoresis
- Adequate hematologic, hepatic and renal function
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
Exclusion Criteria:
- Subject must not have primary refractory disease
- Refractory or non-responsive to prior proteasome inhibitor (PI) therapy (bortezomib or carfilzomib)
- Peripheral neuropathy Grade ≥2 or Grade 1 with pain at Screening
- Plasma cell leukemia, primary amyloidosis, or POEMS syndrome
- Unable to swallow capsules or disease significantly affecting gastrointestinal function
- Requires treatment with strong CYP3A inhibitors
- Women who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibrutinib+ Bortezomib+ Dexamethasone
|
Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
Other Names:
Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
Other Names:
Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects >75 years of age. Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-Free Survival (PFS)
Time Frame: The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Progression-Free Survival (PFS) during their entire time on the study.
|
The primary efficacy endpoint of this study is mPFS.
Progression free survival is defined as the time from the date of first dose of study treatment to confirmed disease progression or death from any cause, whichever occurs first.
|
The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Progression-Free Survival (PFS) during their entire time on the study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Overall Response (OR) during the entire time on the study.
|
Overall Response Rate is the percentage of participants who achieve a PR or better over the course of the study but prior to initiation of subsequent anti-cancer therapy
|
The median time on study was 19.6 months (range: 0.16+, 24.64). Participants were evaluated for Overall Response (OR) during the entire time on the study.
|
Progression Free Survival (PFS) at Landmark Points - 20 Months
Time Frame: The median time on study was 19.6 months (range: 0.16+, 24.64), with the 20 month Progression-Free Survival (PFS) rate presented based on Kaplan-Meier estimates.
|
PFS at landmark points are the percentage of participants without progression (i.e., KM estimates) at the landmark time endpoints.
|
The median time on study was 19.6 months (range: 0.16+, 24.64), with the 20 month Progression-Free Survival (PFS) rate presented based on Kaplan-Meier estimates.
|
Duration of Response (DOR)
Time Frame: The median time on study was 19.6 months (range: 0.16+, 24.64).
|
The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of PD, death, or date of censoring for the participants not progressed/died.
The censoring date is the last adequate tumor assessment date.
|
The median time on study was 19.6 months (range: 0.16+, 24.64).
|
Overall Survival (OS) at 24 Months
Time Frame: The median time on study was 19.6 months (0.16+, 24.64), with the 24 month Overall Survival (OS) rate presented based on Kaplan-Meier estimates.
|
As the median overall survival has not been reached, the data for the landmark analysis at 24 months are provided.
|
The median time on study was 19.6 months (0.16+, 24.64), with the 24 month Overall Survival (OS) rate presented based on Kaplan-Meier estimates.
|
Time to Progression (TTP)
Time Frame: The median time on study was 19.6 months (range: 0.16+, 24.64).
|
Time from date of first dose of study treatment to the date of first documented evidence of PD or date of censoring for the participants not progressed.
The censoring date is the last adequate tumor assessment date.
|
The median time on study was 19.6 months (range: 0.16+, 24.64).
|
Safety and Tolerability of Ibrutinib in Combination With Bortezomib and Dexamethasone as Measured by the Number of Participants With Adverse Events.
Time Frame: From first dose of Ibrutinib to within 30 days of last dose for each participant or until study closure. This is the median treatment duration for Ibrutinib of 5.7 months (range: 0.1 - 23.7 months) +30 days (Adverse Events collection period).
|
Safety and tolerability of ibrutinib in combination with bortezomib and dexamethasone as measured by the frequency and type of adverse events graded using the NCI CTCAE v 4.03.
Frequency and Type of Adverse Events are reported in the Adverse Events module
|
From first dose of Ibrutinib to within 30 days of last dose for each participant or until study closure. This is the median treatment duration for Ibrutinib of 5.7 months (range: 0.1 - 23.7 months) +30 days (Adverse Events collection period).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Bernhard Hauns, MD, Pharmacyclics Switzerland GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Bortezomib
Other Study ID Numbers
- PCYC-1139-CA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRecruitingWaldenstrom MacroglobulinemiaAustria, Germany, Greece
-
TG Therapeutics, Inc.CompletedMantle Cell Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Janssen Research & Development, LLCCompleted
-
Oncternal Therapeutics, IncUniversity of California, San Diego; Pharmacyclics LLC.; California Institute...Active, not recruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia
-
Janssen Research & Development, LLCCompleted
-
Janssen-Cilag S.p.A.CompletedLeukemia, Lymphocytic, Chronic, B-CellItaly
-
The First Affiliated Hospital with Nanjing Medical...Xian-Janssen Pharmaceutical Ltd.UnknownChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaChina
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumTerminatedB-cell LymphomaFrance, Belgium
-
IRCCS San RaffaeleRecruiting